Hepatocellular Carcinoma
Conditions
Keywords
Hepatocellular, Carcinoma, Hepatitis C Virus, Hepatitis B Virus, recurrence, Vitamin K2, E0167
Brief summary
The purpose of this study is to determine the superiority of inhibitory effects and safety of Menatetrenone (E0167) on recurrence in patients with hepatocellular carcinoma.
Detailed description
The study was conducted as a multicenter, randomized, parallel, placebo-controlled, double-blind comparative clinical study. Patients were randomly assigned in a double-blind manner to receive 45 or 90 mg/day of oral vitamin K2 or an identical-appearing placebo. Study drug was administered orally three times daily after meals until recurrence.
Interventions
DRUGMenatetrenone
45 mg capsule, orally, three times a day, after meals.
DRUGPlacebo
Placebo capsule, orally, three times a day, after meals.
Sponsors
Eisai Limited
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. 20 years or older at the time of obtaining consent. 2. Systemic conditions are 0 to 2 score of Performance Status (according to Eastern Cooperative Oncology Group: ECOG). 3. Diagnosis of hepatocellular carcinoma is based on the following 1) or 2). * 1\) Patients who are confirmed to have early tumor stain and typical finding(s) of hepatocellular carcinoma with CT or MRI imaging * 2\) Patients who underwent tumor biopsy and are histopathologically diagnosed as hepatocellular carcinoma 4. Primary onset or recurrence of hepatocellular carcinoma is not more than 1 time. 5. Patients who underwent the following 1) or 2) within 90 days prior to registration to determine therapeutic effect. * 1\) Patients who underwent local therapy to achieve complete hepatonecrosis and are confirmed to have complete hepatonecrosis with CT imaging or MRI. * 2\) Patients who underwent surgical treatment(s) and are confirmed not to have residual tumor with CT or MRI imaging. 6. Patients who meet the following items to determine liver function: * 1\) Albumin is 2.8 g/dL or above * 2\) Total bilirubin is under 2.0 mg/dL * 3\) Prothrombin activation is 40% or above 7. Patients who are given full explanation of study participation (including cancer notification) and submit written consent forms with their understanding as well as voluntary will for this study.
Exclusion criteria
1. Hepatocellular carcinoma: * 1\) Patients who have extrahepatic metastasis * 2\) Patients who have portal invasion * 3\) Patients who experienced with systemic administration of anti-malignant tumor drugs to treat hepatocellular carcinoma * 4\) Patients treated with transcatheter arterial chemoembolization (TAE) alone as a non-local therapy for hepatocellular carcinoma 2. Hepatitis: \-- 1) Patients of (a) or (b) previously treated with interferon preparations (including clinical studies). * (a) Patients with chronic hepatitis C virus (HCV) showing HCV-RNA negative * (b) Patients with viral hepatitis treated with interferon preparations within the last 2 years (from the same day, 6 months earlier to the day of obtaining consent forms) * (c) Patients with encephalopathy in which pharmacotherapy is ineffective * (d) Patients with ascites or pleural effusion that cannot be managed with diuretics 3. Systemic conditions: * 1\) Patients unable to receive oral administration * 2\) Patients with a history of gastrectomy or extensive resection of digestive tract * 3\) Patients who are suspected to have biliary occlusion, choleretic disorder, cholecystectomy, or malabsorption of liposoluble agents * 4\) Patients with complicated serious diseases such as cardiovascular (e.g., myocardial infarction), hematological (e.g., aplastic anemia), and/or renal dysfunctions (e.g., acute and chronic renal failure) * 5\) Patients with multiple cancers (within a 5-year cancer-free period \[from the same day of 5 years earlier to the day of obtaining consent forms\]) 4. Drug administration: * 1\) Patients on warfarin potassium therapy * 2\) Patients with a known history of drug allergy to E0167 or its ingredients * 3\) Patients who received vitamin K preparations within the recent 6 months (from the same day of 6 month earlier to the day of obtaining consent forms) 5. Other
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Relapse-free survival period. | Every 3 months |
Countries
Japan
Outcome results
None listed